MX2024005105A - Metodos para el tratamiento de linfoma folicular recidivante/resistente con mosunetuzumab y lenalidomida. - Google Patents

Metodos para el tratamiento de linfoma folicular recidivante/resistente con mosunetuzumab y lenalidomida.

Info

Publication number
MX2024005105A
MX2024005105A MX2024005105A MX2024005105A MX2024005105A MX 2024005105 A MX2024005105 A MX 2024005105A MX 2024005105 A MX2024005105 A MX 2024005105A MX 2024005105 A MX2024005105 A MX 2024005105A MX 2024005105 A MX2024005105 A MX 2024005105A
Authority
MX
Mexico
Prior art keywords
treatment
mosunetuzumab
lenalidomide
relapsed
methods
Prior art date
Application number
MX2024005105A
Other languages
English (en)
Spanish (es)
Inventor
Chi- Chung LI
michael c Wei
Catherine Granier
Andrea Knapp
Carol Elaine O''hear
Enkhtsetseg Purev
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2024005105A publication Critical patent/MX2024005105A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024005105A 2021-10-29 2021-10-29 Metodos para el tratamiento de linfoma folicular recidivante/resistente con mosunetuzumab y lenalidomida. MX2024005105A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/057439 WO2023075798A1 (en) 2021-10-29 2021-10-29 Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide

Publications (1)

Publication Number Publication Date
MX2024005105A true MX2024005105A (es) 2024-05-14

Family

ID=86158448

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005105A MX2024005105A (es) 2021-10-29 2021-10-29 Metodos para el tratamiento de linfoma folicular recidivante/resistente con mosunetuzumab y lenalidomida.

Country Status (7)

Country Link
JP (2) JP7846761B2 (https=)
KR (1) KR20240093915A (https=)
AU (1) AU2021471006A1 (https=)
CA (1) CA3236111A1 (https=)
MX (1) MX2024005105A (https=)
PE (1) PE20241211A1 (https=)
WO (1) WO2023075798A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026009843A (ja) * 2024-06-25 2026-01-21 ジェネンテック， インコーポレイテッド 単剤療法としてまたはレナリドミドと組み合わせたモスネツズマブの皮下投与を用いてがんを処置する方法
WO2026050474A1 (en) * 2024-08-28 2026-03-05 Genentech, Inc. Subcutaneous dosing of mosunetuzumab in combination with polatuzumab vedotin for use in treating non-hodgkin's lymphoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020275415B2 (en) * 2019-05-14 2026-01-15 Genentech, Inc. Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma

Also Published As

Publication number Publication date
JP2024540044A (ja) 2024-10-31
JP7846761B2 (ja) 2026-04-15
PE20241211A1 (es) 2024-06-06
CA3236111A1 (en) 2023-05-04
WO2023075798A9 (en) 2023-06-29
KR20240093915A (ko) 2024-06-24
AU2021471006A1 (en) 2024-05-16
JP2026004356A (ja) 2026-01-14
WO2023075798A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
CL2024001582A1 (es) Compuestos terapéuticos para la infección por el virus vih
CL2023001949A1 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso (divisional de solicitud de patente no. 3422-2020)
CY1117033T1 (el) Αγωγη εναντι οξειας λεμφοβλαστικης λευχαιμιας
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
CL2019000415A1 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéuticos de una infección por el virus del vih.
CR20190162A (es) Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado
MX2024010591A (es) Compuestos y metodos para el tratamiento de infecciones virales.
EA201792429A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге
MX2024005105A (es) Metodos para el tratamiento de linfoma folicular recidivante/resistente con mosunetuzumab y lenalidomida.
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
CL2021003244A1 (es) Tratamientos de angioedema hereditario
MA32018B1 (fr) Vaccin
EA201791614A1 (ru) Производные индола в качестве ингибиторов репликации вирусов денге
BR112022021562A2 (pt) Partículas interferentes terapêuticas para o coronavírus
MX2020011817A (es) Metodos para tratar el linfoma.
MX2021014680A (es) Derivado de benzotriazol.
CL2023000699A1 (es) Tratamientos de angioedema
MX2022014034A (es) Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta.
PY2295067A (es) Inhibidores del sars-cov-2 para tratar infecciones por coronavirus
CL2024002371A1 (es) Compuestos con estructura en t formada por al menos cuatro ciclos para tratamiento del cáncer
BR112022008183A2 (pt) Formas de sal de um receptor de c5a de componente do complemento
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
MX2022011844A (es) Terapia combinada con un inhibidor de idh mutante.
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
MX2011006516A (es) Terapia de combinacion de virus de hepatitis c.